US20100069900A1 - Dual balloon catheter assembly - Google Patents
Dual balloon catheter assembly Download PDFInfo
- Publication number
- US20100069900A1 US20100069900A1 US12/233,349 US23334908A US2010069900A1 US 20100069900 A1 US20100069900 A1 US 20100069900A1 US 23334908 A US23334908 A US 23334908A US 2010069900 A1 US2010069900 A1 US 2010069900A1
- Authority
- US
- United States
- Prior art keywords
- balloon
- inner balloon
- catheter assembly
- fluid
- coolant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000009977 dual effect Effects 0.000 title abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000001028 anti-proliverative effect Effects 0.000 claims abstract description 21
- 239000002826 coolant Substances 0.000 claims description 50
- 239000012530 fluid Substances 0.000 claims description 48
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 35
- 239000011148 porous material Substances 0.000 claims description 20
- 238000004891 communication Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229940124597 therapeutic agent Drugs 0.000 claims description 16
- 229930012538 Paclitaxel Natural products 0.000 claims description 13
- 229960001592 paclitaxel Drugs 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 10
- 230000010339 dilation Effects 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000009696 proliferative response Effects 0.000 abstract description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 14
- 239000007788 liquid Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 10
- 239000001272 nitrous oxide Substances 0.000 description 7
- 210000004351 coronary vessel Anatomy 0.000 description 6
- 239000007789 gas Substances 0.000 description 6
- 208000031481 Pathologic Constriction Diseases 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 230000036262 stenosis Effects 0.000 description 5
- 208000037804 stenosis Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000009529 body temperature measurement Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000009530 blood pressure measurement Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- -1 polyethylene Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 239000012809 cooling fluid Substances 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011555 saturated liquid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00053—Mechanical features of the instrument of device
- A61B2018/00214—Expandable means emitting energy, e.g. by elements carried thereon
- A61B2018/0022—Balloons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0212—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques using an instrument inserted into a body lumen, e.g. catheter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/02—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by cooling, e.g. cryogenic techniques
- A61B2018/0231—Characteristics of handpieces or probes
- A61B2018/0262—Characteristics of handpieces or probes using a circulating cryogenic fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
- A61M2025/1013—Multiple balloon catheters with concentrically mounted balloons, e.g. being independently inflatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Definitions
- the present invention relates generally to medical devices and more particularly to balloon catheters used to dilate narrowed portions of a lumen.
- Balloon catheters are widely used in the medical profession for various intraluminal procedures.
- One common procedure involving the use of a balloon catheter relates to angioplasty dilation of coronary or other arteries suffering from stenosis (i.e., a narrowing of the arterial lumen that restricts blood flow).
- bypass surgery involves splitting the chest bone to open the chest cavity and grafting a replacement vessel onto the heart to bypass the blocked, or stenosed, artery.
- coronary bypass surgery is a very invasive procedure that is risky and requires a long recovery time for the patient.
- angioplasty procedures are performed using a balloon-tipped catheter that may or may not have a stent mounted on the balloon (also referred to as a stented catheter).
- the physician performs the angioplasty procedure by introducing the balloon catheter into a peripheral artery (commonly one of the leg arteries) and threading the catheter to the narrowed part of the coronary artery to be treated.
- the balloon is uninflated and collapsed onto the shaft of the catheter in order to present a low profile which may be passed through the arterial lumens.
- the balloon is expanded by pumping an inflation solution through the catheter to the balloon.
- the balloon presses against the inner wall of the artery to dilate it.
- Typical inflated pressures of the balloon may range between about 6 atm to about 20 atm (i.e, 90 psi- 300 psi).
- the balloon inflation also serves to expand the stent and implant it within the artery.
- the balloon is deflated so that it once again collapses onto the shaft of the catheter. The balloon-tipped catheter is then retracted from the body.
- a stent is mounted on the balloon of the catheter, the stent is left permanently implanted in its expanded state at the desired location in the artery to provide a support structure that prevents the artery from collapsing back to its pre-dilated condition.
- the balloon catheter is not adapted for delivery of a stent, either a balloon-expandable stent or a self-expandable stent may be implanted in the dilated region in a follow-up procedure.
- the invention may include any of the following aspects in various combinations and may also include any other aspect described below in the written description or in the attached drawings.
- a double balloon catheter assembly for dilation of a vessel wall.
- the assembly comprises a non-porous inner balloon having a proximal portion, a distal portion, and an outer surface extending between the proximal and the distal portions. At least a portion of the outer surface of the inner balloon is pre-coated with therapeutic agent so as to be subsequently entrained by a fluid.
- the outer balloon is radially spaced apart from the inner balloon by an annular lumen.
- the outer balloon comprises pores in fluid communication with the annular lumen. The pores are sized to pass the therapeutic agent therethrough.
- a shaft is also provided having a distal end and a proximal end. The inner and the outer balloons are mounted on the distal end of the shaft.
- the shaft comprises an inflation lumen extending therethrough in fluid communication with an interior region of the inner balloon to expand the inner balloon between a deflated state and an inflated state.
- a balloon catheter assembly comprising a non-porous inner balloon, the inner balloon having an outer surface wherein at least a portion of the outer surface is pre-coated with a therapeutic agent.
- the assembly further comprises an outer balloon disposed over the inner balloon, the outer balloon being spaced apart from the inner balloon by an annular lumen.
- the outer balloon has a porous structure. Fluid is introduced into the annular lumen.
- the inner balloon is inflated so as to push out the outer balloon against the stenosed vessel wall.
- Therapeutic agent is eluted with the fluid through the pores of the outer surface of the outer balloon and into the vessel wall.
- a double cryoplasty balloon catheter assembly for dilation of a vessel wall.
- a non-porous inner balloon is provided having a proximal portion and a distal portion.
- the inner balloon is configured to receive a predetermined amount of cryogenic coolant sufficient to cool the inner balloon to a temperature adapted to induce apoptosis.
- the assembly further comprises an outer balloon disposed over the inner balloon.
- the outer balloon is radially spaced apart from the inner balloon by an annular lumen.
- the outer balloon comprises pores in fluid communication with the annular lumen.
- a shaft having a distal end and a proximal end is provided for mounting the inner and the outer balloons along the distal end of the shaft.
- the shaft comprises an inflation lumen extending therethrough in fluid communication with an interior region of the inner balloon to expand the inner balloon between a deflated state and an inflated state.
- a balloon catheter assembly comprising an inner balloon.
- the inner balloon has an outer surface wherein at least a portion of the outer surface is coated with an antiproliferative.
- the assembly further comprising an outer balloon disposed over the inner balloon, in which the outer balloon is spaced apart from the inner balloon by an annular lumen.
- the outer balloon has a porous structure.
- a cryogenic pressurized flow of coolant is introduced from a supply of cryogenic coolant into the inner balloon.
- a flow of fluid is introduced through the annular lumen.
- the inner balloon is inflated so as to push out the outer balloon against the stenosed vessel wall.
- the interior volume of the inner balloon is cooled to a temperature sufficient to induce apoptosis of the stenosed vessel wall.
- An antiproliferative is eluted with the fluid through the pores of the outer surface of the balloon into the vessel wall.
- FIG. 1 shows an exemplary dual balloon assembly
- FIG. 2 shows the dual balloon assembly of FIG. 1 being utilized in a cryoplasty procedure
- FIG. 3 is a cross-sectional view of the dual balloon assembly of FIG. 1 taken along line 3 - 3 of catheter shaft;
- FIG. 4 shows components of a feedback control system for regulating, initiating, and ceasing the supply of cryogenic coolant
- FIG. 5 shows a saturated liquid-vapor curve for nitrous oxide.
- FIGS. 1 and 2 An exemplary dual balloon assembly 100 is shown in FIGS. 1 and 2 .
- the dual balloon assembly 100 includes an inner inflation balloon 120 and a perforated outer balloon 130 .
- the perforated outer balloon 130 is radially disposed around the inner inflation balloon 120 .
- the inner balloon 120 is in fluid communication with inflation port 260 ( FIG. 2 ) through the body of catheter shaft 202 .
- the outer balloon 130 is in fluid communication with inflation port 201 through the catheter shaft 202 .
- An annular lumen 103 FIGS. 1 and 2 ) for receiving fluid 261 (e.g., saline) from inflation port 201 is formed between the inner inflation balloon 120 and the perforated outer balloon 130 .
- fluid 261 e.g., saline
- the annular lumen 103 is in fluid communication with pores 210 extending along at least a portion of outer balloon 130 .
- the pores 210 allow material (e.g., fluid and therapeutic agents 190 contained within the fluid) to pass therethrough.
- the inner balloon 120 and outer balloon 130 may be sealed to the distal end 205 of catheter shaft 202 .
- the dual balloon assembly 100 may be used for various applications, including delivery of a therapeutic agent 190 locally to tissue while simultaneously dilating a body vessel through pores 210 of the outer balloon 130 .
- a therapeutic agent 190 to a dilated portion of a coronary artery in a PTCA procedure.
- the inner balloon 120 may be inflated to a desired diameter in a body vessel such as a coronary artery by injecting a suitable inflation fluid, such as pressurized air, gas, or liquid through the inflation port 260 .
- the inner balloon 120 may be inflated until the outer balloon 130 contacts a portion of the body vessel wall at a point of treatment.
- a fluid 261 containing a therapeutic agent 190 and/or a diagnostic agent may be injected through the injection port 201 , transported within the catheter shaft 202 , and introduced through annular lumen 103 between the outer balloon 130 and the inner balloon 120 .
- the therapeutic agent may be pressurized to deliver the agent through the wall of a body vessel through the pores 210 in the outer balloon 130 before, during, or after inflation of the inner balloon 120 .
- the therapeutic agent is eluted through the pores 210 before complete inflation of inner balloon 120 .
- the dual balloon assembly 100 is used in a cryoplasty procedure in which the inner balloon 120 functions as a cryoplasty balloon. At least a portion of the outer surface 231 of the inner balloon 120 may be loaded with an antiproliferative 190 .
- the antiproliferative is paclitaxel.
- FIGS. 1 and 2 show a layer of antiproliferative 190 coated along a working diameter of the outer surface 231 of the inner balloon 120 . Alternatively, the entire outer surface 231 of inner balloon 120 may be coated with the antiproliferative 190 .
- the balloon catheter assembly 100 is initially delivered to a stenosed vessel region 180 .
- the assembly 100 preferably is configured to receive a wire guide through wire guide lumen 320 ( FIG. 3 ).
- the assembly 100 is advanced along the wire guide. Having reached the stenosed vessel region 180 , the cryoplasty procedure may ensue.
- the cryogenic coolant 170 may be introduced from a fluid supply source such as a canister 193 ( FIG. 2 ), which contains the coolant 170 in the form of a high pressure liquid.
- Suitable cryogenic coolants are non-toxic and are usually in the form of a liquid refrigerant or liquid/gas mixture within canister 193 .
- the cryogenic coolant 170 as contained in the canister 193 may include liquid nitrous oxide, liquid saline, liquid nitrogen, liquid carbon dioxide, and the like.
- the canister 193 comprises high pressure liquefied nitrous oxide at a saturation pressure of about 500 psi and at a saturation temperature of about 0° C.
- a control valve 209 opens for a time sufficient to introduce a predetermined amount of cryogenic coolant 170 as a saturated liquid into port 260 .
- the valve 209 may be open for less than a second to introduce cryogenic coolant 170 into the proximal port 260 of the balloon catheter 100 ( FIG. 2 ).
- the coolant 170 is liquefied nitrous oxide.
- the liquefied nitrous oxide coolant 170 emerges from canister 193 at about 500 psi and about 0 C.
- the coolant 170 travels along catheter shaft 202 within a coolant lumen 322 ( FIG. 3 ) of shaft 202 . Some of the coolant 170 may flash vaporize from liquid to gas as it travels along the catheter shaft 202 .
- the coolant 170 As the coolant 170 enters the interior of the inner balloon 120 , as indicated by arrows “A” in FIG. 2 , the coolant 170 experiences a reduction in pressure in which at least a portion of the liquid coolant 170 flashes into vapor. Both the vapor and any residual liquid of coolant 170 are cooled to the saturation temperature of the coolant 170 along the saturation curve for nitrous oxide, in the direction of the arrow shown in FIG. 5 .
- the cryogenic coolant 170 flows into the interior of inner balloon 120 and cools the interior of the inner balloon 120 and outer surface 231 of inner balloon 120 . This infusion of a predetermined amount of cryogenic coolant 170 into inner balloon 120 simultaneously cools and partially inflates the inner balloon 120 .
- a predetermined amount of time (e.g., 10-25 seconds) may be allowed to transpire before a temperature reading may be sensed by temperature sensor 175 , which is shown affixed to an outer surface 231 of inner balloon 120 in FIG. 2 .
- the temperature sensor 175 transmits a temperature electrical signal 197 ( FIGS. 2 and 4 ) to controller 192 .
- Controller 192 may function to initiate, monitor, and control cooling of the target tissue at stenosed region 180 ( FIG. 1 ).
- the controller 192 reads the temperature measurement provided by temperature sensor 175 via electrical signal 197 .
- the controller 192 evaluates whether additional coolant 170 is required to be fed into inner balloon 120 from the canister 193 and then sends the appropriate electric signal 195 to the control valve 209 for cryogenic fluid supply canister 193 (i.e., cooling fluid supply feed). If additional coolant 170 is determined necessary by controller 192 , the signal 195 causes control valve 209 to open from its closed position for a predetermined amount of time (e.g., about 1 second) to allow a predetermined amount of coolant 170 to be introduced through port 260 of the catheter shaft 202 .
- a predetermined amount of time e.g., about 1 second
- the control valve 209 continues to open and close until the desired cooling and inflation pressure have occurred within inner and outer balloons 120 and 130 .
- the opening and subsequent closing of control valve 209 to introduce a predetermined amount of coolant 170 constitutes a “cycle.”
- multiple cooling “cycles” may be required to reach the desired pressure level (e.g., 8-10 atm) and cooling temperature (e.g., about ⁇ 5° C.-10° C.) within inner balloon 120 .
- the controller 192 may regulate the flow of coolant 170 in a cycled manner based on temperature measurements.
- Temperature measurements of the outer balloon 130 may also be provided by temperature sensor 201 .
- the controller 192 may then regulate flow of coolant 170 based on a temperature electrical signal 198 ( FIGS. 2 and 4 ) that is transmitted from temperature sensor 201 .
- the regulation of flow of coolant 170 may be based on pressure measurements.
- Pressure sensor 176 is shown affixed to an interior surface of inner balloon 120 as shown in FIG. 2 .
- the pressure sensor 176 transmits a pressure electrical signal 196 to controller 192 ( FIGS. 2 and 4 ).
- the controller 192 reads the pressure measurement provided by pressure sensor 176 and then evaluates whether additional coolant 170 is required to be fed to inner balloon 120 from the canister 193 .
- control valve 209 opens from its closed position for a predetermined amount of time (e.g., about 1 second) to allow a predetermined amount of coolant 170 to be introduced through port 260 of the catheter shaft 202 .
- the time at which the control valve 209 opens and closes and the duration for keeping the control valve 209 opened and closed is determined by controller 192 .
- the inner balloon 120 may reach a fully inflated state in a time from about 0.2 seconds to about 20 seconds after introduction of the coolant 170 into shaft 202 .
- the inner balloon 120 pressure may be further controlled by a pressure relief valve 219 shown in FIGS. 2 and 4 . Similar to control valve 209 , the pressure relief valve 219 is in electrical communication with controller 192 . Excess pressure within balloon 120 may be relieved through exhaust lumen 325 ( FIG. 3 ). FIG. 3 shows that the exhaust lumen 325 is preferably larger relative to the other lumens 320 , 321 , and 322 in order to be capable of exhausting a large volume of coolant 170 gas relatively quickly. Excess pressure may be detected by pressure sensor 176 ( FIG. 1 ) via pressure electrical signal 196 . Controller receives signal 196 and then transmits pressure relief electrical signal 218 ( FIG. 4 ) to pressure relief valve 219 . Signal 218 causes valve 219 to open for a predetermined amount of time to enable excess coolant 170 gas to be relieved into enclosed container 211 ( FIG. 2 ).
- FIG. 5 is a liquid-vapor saturation curve for a nitrous oxide cryogenic coolant.
- 100 psia i.e., about 7 atm
- the temperature inside inner balloon 120 will be about ⁇ 50° C.
- 150 psia about 10 atm
- the temperature inside inner balloon 120 will be about ⁇ 38° C.
- such inner balloon 120 temperatures may result in the appropriate cooling of the tissue surrounding stenosed vessel region 180 to about ⁇ 5° C. to about ⁇ 10° C.
- the body tissue is cooled to a temperature from about ⁇ 5° C. to about ⁇ 15° C. to induce programmed cell death of the body tissue, otherwise known in the art as apoptosis.
- Other suitable coolants may have different liquid-vapor saturation curves which will result in a different pressure and temperature within inner balloon 120 .
- the inner balloon 120 begins to press against outer balloon 130 , thereby reducing the free space within the annular lumen 103 .
- the flow of fluid 261 may encounter increased resistance such that elution of entrained antiproliferative 1 90 through the pores 210 may become increasingly difficult to achieve.
- a fluid 261 is injected at port 201 and thereafter along catheter shaft 202 within lumen 321 ( FIG. 3 ).
- Introduction of fluid 261 is preferably not designed to generate sufficient inflation pressure of outer balloon 130 .
- the fluid 261 flows between the inner and outer balloons 120 and 130 , as indicated by arrows “B”.
- the fluid 261 contacts outer surface 231 of inner balloon 220 .
- As the fluid 261 ( FIG. 1 ) contacts outer surface 231 it entrains (i.e., picks up) the antiproliferative 190 and thereby functions as a liquid carrier for the antiproliferative 190 .
- Fluid 261 may be any suitable fluid that is biocompatible with the particular antiproliferative 190 being used.
- the antiproliferative 190 being utilized is paclitaxel.
- the fluid 261 used for entraining the paclitaxel may include alcohol, ethanol, iodine contrast imaging agent, and saline.
- Suitable fluids 261 for entraining paclitaxel include medical grade saline solution and various Cremophore solvents. Thereafter, the fluid 261 with entrained paclitaxel 190 flows out through pores 210 of the outer balloon 130 and into the stenosed region 180 .
- the paclitaxel 190 may be applied to the outer surface 231 of the inner balloon 120 by coating.
- the paclitaxel 190 may be coated along the entire outer surface 231 of inner balloon 120 in a variety of effective dosage amounts, including about 3 pg per mm 2 of surface area of the outer surface 231 .
- Between about 5 to about 10 cc of fluid 261 may be introduced through annular lumen 103 to entrain the paclitaxel 190 through pores 210 of the outer balloon 130 .
- coolant 170 and fluid 261 may be simultaneously introduced through their respective lumens 322 and 321 ( FIG. 3 ) of catheter shaft 202 .
- the outer surface of outer balloon 130 comes into direct contact with stenosed region 180 to cool the target tissue.
- all of the paclitaxel 190 is eluted into the target tissue of the stenosed vessel 180 prior to the outer balloon 130 contacting the tissue surrounding the stenosed region 180 .
- elution may occur after or simultaneously with cooling of tissue surrounding region 180 .
- fluid flow 261 and coolant flow 170 may cease.
- the coolant 170 gas within the inner balloon 120 is exhausted preferably by vacuum through exhaust lumen 325 ( FIG. 3 ) of catheter shaft 202 .
- the combination of cryoplasty treatment with an antiproliferative 190 may reduce and/or eliminate vessel fractures, thereby inhibiting proliferative response after angioplasty procedures.
- the above procedure offers the advantage of the dual balloon assembly 100 being pre-coated with the antiproliferative 190 .
- the practitioner need not be concerned about injecting the antiproliferative 190 at a predetermined drug delivery rate during the procedure.
- the outer balloon 130 may be formed from a material that acts as a thermal insulator.
- FIGS. 1 and 2 show that a thermal barrier 310 may be disposed along at least a portion of the outer surface 231 of the inner balloon 120 .
- Suitable thermal barriers 310 may include textiles (e.g., polyethylene) as are commonly used in the art to form vascular grafts.
- thermal barriers 310 may include polyethylene terepthalate (PET) or polyethylene napthlate (PEN) affixed to the outer surface 231 by adhesion bonding, heat welding, fasteners, or the like.
- PET polyethylene terepthalate
- PEN polyethylene napthlate
- FIG. 3 shows that the thermal barrier layer 310 is disposed between an outer surface 231 of inner balloon 120 and the antiproliferative layer 190 .
- the thermal barrier 310 may comprise a sleeve that is wrapped around the outer surface 231 of inner balloon 120 .
Abstract
Description
- The present invention relates generally to medical devices and more particularly to balloon catheters used to dilate narrowed portions of a lumen.
- Balloon catheters are widely used in the medical profession for various intraluminal procedures. One common procedure involving the use of a balloon catheter relates to angioplasty dilation of coronary or other arteries suffering from stenosis (i.e., a narrowing of the arterial lumen that restricts blood flow).
- Although balloon catheters are used in many other procedures as well, coronary angioplasty using a balloon catheter has drawn particular attention from the medical community because of the growing number of people suffering from heart problems associated with stenosis. This has lead to an increased demand for medical procedures to treat such problems. The widespread frequency of heart problems may be due to a number of societal changes, including the tendency of people to exercise less while eating greater quantities of unhealthy foods, in conjunction with the fact that people generally now have longer life spans than previous generations. Angioplasty procedures have become a popular alternative for treating coronary stenosis because angioplasty procedures are considerably less invasive than other alternatives. For example, stenosis of the coronary arteries has traditionally been treated with bypass surgery. In general, bypass surgery involves splitting the chest bone to open the chest cavity and grafting a replacement vessel onto the heart to bypass the blocked, or stenosed, artery. However, coronary bypass surgery is a very invasive procedure that is risky and requires a long recovery time for the patient.
- To address the increased need for coronary artery treatments, the medical community has turned to angioplasty procedures, in combination with stenting procedures, to avoid the problems associated with traditional bypass surgery. Typically, angioplasty procedures are performed using a balloon-tipped catheter that may or may not have a stent mounted on the balloon (also referred to as a stented catheter). The physician performs the angioplasty procedure by introducing the balloon catheter into a peripheral artery (commonly one of the leg arteries) and threading the catheter to the narrowed part of the coronary artery to be treated. During this stage, the balloon is uninflated and collapsed onto the shaft of the catheter in order to present a low profile which may be passed through the arterial lumens. Once the balloon is positioned at the narrowed part of the artery, the balloon is expanded by pumping an inflation solution through the catheter to the balloon. As a result, the balloon presses against the inner wall of the artery to dilate it. Typical inflated pressures of the balloon may range between about 6 atm to about 20 atm (i.e, 90 psi-300 psi). If a stent is mounted on the balloon, the balloon inflation also serves to expand the stent and implant it within the artery. After the artery is dilated, the balloon is deflated so that it once again collapses onto the shaft of the catheter. The balloon-tipped catheter is then retracted from the body. If a stent is mounted on the balloon of the catheter, the stent is left permanently implanted in its expanded state at the desired location in the artery to provide a support structure that prevents the artery from collapsing back to its pre-dilated condition. On the other hand, if the balloon catheter is not adapted for delivery of a stent, either a balloon-expandable stent or a self-expandable stent may be implanted in the dilated region in a follow-up procedure. Although the treatment of stenosed coronary arteries is one common example where balloon catheters have been used, this is only one example of how balloon catheters may be used and many other uses are also possible.
- One problem that may be encountered with conventional angioplasty techniques is the proper dilation of stenosed regions that are hardened and/or have become calcified. Stenosed regions may become hardened for a variety of reasons, such as the buildup of atherosclerotic plaque or other substances. Hardened regions of stenosis can be difficult to completely dilate using conventional balloons because hardened regions tend to resist the expansion pressures applied by conventional balloon catheters.
- Although the inventions described below may be useful in treating hardened regions of stenosis, the claimed inventions may also solve other problems as well.
- The invention may include any of the following aspects in various combinations and may also include any other aspect described below in the written description or in the attached drawings.
- In a first aspect, a double balloon catheter assembly for dilation of a vessel wall is provided. The assembly comprises a non-porous inner balloon having a proximal portion, a distal portion, and an outer surface extending between the proximal and the distal portions. At least a portion of the outer surface of the inner balloon is pre-coated with therapeutic agent so as to be subsequently entrained by a fluid. The outer balloon is radially spaced apart from the inner balloon by an annular lumen. The outer balloon comprises pores in fluid communication with the annular lumen. The pores are sized to pass the therapeutic agent therethrough. A shaft is also provided having a distal end and a proximal end. The inner and the outer balloons are mounted on the distal end of the shaft. The shaft comprises an inflation lumen extending therethrough in fluid communication with an interior region of the inner balloon to expand the inner balloon between a deflated state and an inflated state.
- In a second aspect, a method for treating a stenosed vessel wall is provided. A balloon catheter assembly is provided comprising a non-porous inner balloon, the inner balloon having an outer surface wherein at least a portion of the outer surface is pre-coated with a therapeutic agent. The assembly further comprises an outer balloon disposed over the inner balloon, the outer balloon being spaced apart from the inner balloon by an annular lumen. The outer balloon has a porous structure. Fluid is introduced into the annular lumen. The inner balloon is inflated so as to push out the outer balloon against the stenosed vessel wall. Therapeutic agent is eluted with the fluid through the pores of the outer surface of the outer balloon and into the vessel wall.
- In a third aspect, a double cryoplasty balloon catheter assembly for dilation of a vessel wall is provided. A non-porous inner balloon is provided having a proximal portion and a distal portion. The inner balloon is configured to receive a predetermined amount of cryogenic coolant sufficient to cool the inner balloon to a temperature adapted to induce apoptosis. The assembly further comprises an outer balloon disposed over the inner balloon. The outer balloon is radially spaced apart from the inner balloon by an annular lumen. The outer balloon comprises pores in fluid communication with the annular lumen. A shaft having a distal end and a proximal end is provided for mounting the inner and the outer balloons along the distal end of the shaft. The shaft comprises an inflation lumen extending therethrough in fluid communication with an interior region of the inner balloon to expand the inner balloon between a deflated state and an inflated state.
- In a fourth aspect, a method for treating a stenosed vessel wall is provided. A balloon catheter assembly is provided comprising an inner balloon. The inner balloon has an outer surface wherein at least a portion of the outer surface is coated with an antiproliferative. The assembly further comprising an outer balloon disposed over the inner balloon, in which the outer balloon is spaced apart from the inner balloon by an annular lumen. The outer balloon has a porous structure. A cryogenic pressurized flow of coolant is introduced from a supply of cryogenic coolant into the inner balloon. A flow of fluid is introduced through the annular lumen. The inner balloon is inflated so as to push out the outer balloon against the stenosed vessel wall. The interior volume of the inner balloon is cooled to a temperature sufficient to induce apoptosis of the stenosed vessel wall. An antiproliferative is eluted with the fluid through the pores of the outer surface of the balloon into the vessel wall.
- The invention may be more fully understood by reading the following description in conjunction with the drawings, in which:
-
FIG. 1 shows an exemplary dual balloon assembly; -
FIG. 2 shows the dual balloon assembly ofFIG. 1 being utilized in a cryoplasty procedure; -
FIG. 3 is a cross-sectional view of the dual balloon assembly ofFIG. 1 taken along line 3-3 of catheter shaft; -
FIG. 4 shows components of a feedback control system for regulating, initiating, and ceasing the supply of cryogenic coolant; and -
FIG. 5 shows a saturated liquid-vapor curve for nitrous oxide. - An exemplary
dual balloon assembly 100 is shown inFIGS. 1 and 2 . Thedual balloon assembly 100 includes aninner inflation balloon 120 and a perforatedouter balloon 130. The perforatedouter balloon 130 is radially disposed around theinner inflation balloon 120. Theinner balloon 120 is in fluid communication with inflation port 260 (FIG. 2 ) through the body ofcatheter shaft 202. Theouter balloon 130 is in fluid communication withinflation port 201 through thecatheter shaft 202. An annular lumen 103 (FIGS. 1 and 2 ) for receiving fluid 261 (e.g., saline) frominflation port 201 is formed between theinner inflation balloon 120 and the perforatedouter balloon 130. Theannular lumen 103 is in fluid communication withpores 210 extending along at least a portion ofouter balloon 130. Thepores 210 allow material (e.g., fluid andtherapeutic agents 190 contained within the fluid) to pass therethrough. Theinner balloon 120 andouter balloon 130 may be sealed to thedistal end 205 ofcatheter shaft 202. - The
dual balloon assembly 100 may be used for various applications, including delivery of atherapeutic agent 190 locally to tissue while simultaneously dilating a body vessel throughpores 210 of theouter balloon 130. One example includes delivery of atherapeutic agent 190 to a dilated portion of a coronary artery in a PTCA procedure. In particular, theinner balloon 120 may be inflated to a desired diameter in a body vessel such as a coronary artery by injecting a suitable inflation fluid, such as pressurized air, gas, or liquid through theinflation port 260. Theinner balloon 120 may be inflated until theouter balloon 130 contacts a portion of the body vessel wall at a point of treatment. A fluid 261 containing atherapeutic agent 190 and/or a diagnostic agent (e.g., fluoroscopic contrast media) may be injected through theinjection port 201, transported within thecatheter shaft 202, and introduced throughannular lumen 103 between theouter balloon 130 and theinner balloon 120. The therapeutic agent may be pressurized to deliver the agent through the wall of a body vessel through thepores 210 in theouter balloon 130 before, during, or after inflation of theinner balloon 120. Preferably, the therapeutic agent is eluted through thepores 210 before complete inflation ofinner balloon 120. - Other applications utilizing the
dual balloon assembly 100 are also contemplated. In a preferred embodiment, thedual balloon assembly 100 is used in a cryoplasty procedure in which theinner balloon 120 functions as a cryoplasty balloon. At least a portion of theouter surface 231 of theinner balloon 120 may be loaded with an antiproliferative 190. Preferably, the antiproliferative is paclitaxel.FIGS. 1 and 2 show a layer ofantiproliferative 190 coated along a working diameter of theouter surface 231 of theinner balloon 120. Alternatively, the entireouter surface 231 ofinner balloon 120 may be coated with the antiproliferative 190. - In cryoplasty operation, the
balloon catheter assembly 100 is initially delivered to astenosed vessel region 180. Theassembly 100 preferably is configured to receive a wire guide through wire guide lumen 320 (FIG. 3 ). Theassembly 100 is advanced along the wire guide. Having reached thestenosed vessel region 180, the cryoplasty procedure may ensue. Thecryogenic coolant 170 may be introduced from a fluid supply source such as a canister 193 (FIG. 2 ), which contains thecoolant 170 in the form of a high pressure liquid. Suitable cryogenic coolants are non-toxic and are usually in the form of a liquid refrigerant or liquid/gas mixture withincanister 193. Thecryogenic coolant 170 as contained in thecanister 193 may include liquid nitrous oxide, liquid saline, liquid nitrogen, liquid carbon dioxide, and the like. In one example, thecanister 193 comprises high pressure liquefied nitrous oxide at a saturation pressure of about 500 psi and at a saturation temperature of about 0° C. - A
control valve 209 opens for a time sufficient to introduce a predetermined amount ofcryogenic coolant 170 as a saturated liquid intoport 260. Thevalve 209 may be open for less than a second to introducecryogenic coolant 170 into theproximal port 260 of the balloon catheter 100 (FIG. 2 ). In this example, thecoolant 170 is liquefied nitrous oxide. The liquefiednitrous oxide coolant 170 emerges fromcanister 193 at about 500 psi and about 0C. Thecoolant 170 travels alongcatheter shaft 202 within a coolant lumen 322 (FIG. 3 ) ofshaft 202. Some of thecoolant 170 may flash vaporize from liquid to gas as it travels along thecatheter shaft 202. As thecoolant 170 enters the interior of theinner balloon 120, as indicated by arrows “A” inFIG. 2 , thecoolant 170 experiences a reduction in pressure in which at least a portion of theliquid coolant 170 flashes into vapor. Both the vapor and any residual liquid ofcoolant 170 are cooled to the saturation temperature of thecoolant 170 along the saturation curve for nitrous oxide, in the direction of the arrow shown inFIG. 5 . Thecryogenic coolant 170 flows into the interior ofinner balloon 120 and cools the interior of theinner balloon 120 andouter surface 231 ofinner balloon 120. This infusion of a predetermined amount ofcryogenic coolant 170 intoinner balloon 120 simultaneously cools and partially inflates theinner balloon 120. A predetermined amount of time (e.g., 10-25 seconds) may be allowed to transpire before a temperature reading may be sensed bytemperature sensor 175, which is shown affixed to anouter surface 231 ofinner balloon 120 inFIG. 2 . Thetemperature sensor 175 transmits a temperature electrical signal 197 (FIGS. 2 and 4 ) tocontroller 192.Controller 192 may function to initiate, monitor, and control cooling of the target tissue at stenosed region 180 (FIG. 1 ). - Referring to
FIGS. 2 and 4 , thecontroller 192 reads the temperature measurement provided bytemperature sensor 175 viaelectrical signal 197. Thecontroller 192 evaluates whetheradditional coolant 170 is required to be fed intoinner balloon 120 from thecanister 193 and then sends the appropriateelectric signal 195 to thecontrol valve 209 for cryogenic fluid supply canister 193 (i.e., cooling fluid supply feed). Ifadditional coolant 170 is determined necessary bycontroller 192, thesignal 195 causes controlvalve 209 to open from its closed position for a predetermined amount of time (e.g., about 1 second) to allow a predetermined amount ofcoolant 170 to be introduced throughport 260 of thecatheter shaft 202. Thecontrol valve 209 continues to open and close until the desired cooling and inflation pressure have occurred within inner andouter balloons control valve 209 to introduce a predetermined amount ofcoolant 170 constitutes a “cycle.” Generally, multiple cooling “cycles” may be required to reach the desired pressure level (e.g., 8-10 atm) and cooling temperature (e.g., about −5° C.-10° C.) withininner balloon 120. As a result, thecontroller 192 may regulate the flow ofcoolant 170 in a cycled manner based on temperature measurements. - Temperature measurements of the
outer balloon 130 may also be provided bytemperature sensor 201. Thecontroller 192 may then regulate flow ofcoolant 170 based on a temperature electrical signal 198 (FIGS. 2 and 4 ) that is transmitted fromtemperature sensor 201. - Alternatively or in addition to the above described temperature measurements, the regulation of flow of
coolant 170 may be based on pressure measurements.Pressure sensor 176 is shown affixed to an interior surface ofinner balloon 120 as shown inFIG. 2 . Thepressure sensor 176 transmits a pressureelectrical signal 196 to controller 192 (FIGS. 2 and 4 ). Thecontroller 192 reads the pressure measurement provided bypressure sensor 176 and then evaluates whetheradditional coolant 170 is required to be fed toinner balloon 120 from thecanister 193. Ifadditional coolant 170 is determined necessary bycontroller 192,control valve 209 opens from its closed position for a predetermined amount of time (e.g., about 1 second) to allow a predetermined amount ofcoolant 170 to be introduced throughport 260 of thecatheter shaft 202. The time at which thecontrol valve 209 opens and closes and the duration for keeping thecontrol valve 209 opened and closed is determined bycontroller 192. In one example, theinner balloon 120 may reach a fully inflated state in a time from about 0.2 seconds to about 20 seconds after introduction of thecoolant 170 intoshaft 202. - The
inner balloon 120 pressure may be further controlled by apressure relief valve 219 shown inFIGS. 2 and 4 . Similar to controlvalve 209, thepressure relief valve 219 is in electrical communication withcontroller 192. Excess pressure withinballoon 120 may be relieved through exhaust lumen 325 (FIG. 3 ).FIG. 3 shows that theexhaust lumen 325 is preferably larger relative to theother lumens coolant 170 gas relatively quickly. Excess pressure may be detected by pressure sensor 176 (FIG. 1 ) via pressureelectrical signal 196. Controller receivessignal 196 and then transmits pressure relief electrical signal 218 (FIG. 4 ) topressure relief valve 219.Signal 218 causesvalve 219 to open for a predetermined amount of time to enableexcess coolant 170 gas to be relieved into enclosed container 211 (FIG. 2 ). - As can be seen from
FIG. 5 , the type of cryogenic coolant governs the resultant cooling and inflation pressures withininner balloon 120.FIG. 5 is a liquid-vapor saturation curve for a nitrous oxide cryogenic coolant. At 100 psia (i.e., about 7 atm), which is within the range of typical operating pressure for angioplasty balloons, the temperature insideinner balloon 120 will be about −50° C. At 150 psia (about 10 atm), the temperature insideinner balloon 120 will be about −38° C. Taking into account the temperature difference between theinner balloon 120 and the target tissue, suchinner balloon 120 temperatures may result in the appropriate cooling of the tissue surroundingstenosed vessel region 180 to about −5° C. to about −10° C. Preferably, the body tissue is cooled to a temperature from about −5° C. to about −15° C. to induce programmed cell death of the body tissue, otherwise known in the art as apoptosis. Other suitable coolants may have different liquid-vapor saturation curves which will result in a different pressure and temperature withininner balloon 120. - As the
inner balloon 120 gradually expands as described above, theinner balloon 120 begins to press againstouter balloon 130, thereby reducing the free space within theannular lumen 103. As the free space withinannular lumen 103 compresses, the flow offluid 261 may encounter increased resistance such that elution of entrained antiproliferative 1 90 through thepores 210 may become increasingly difficult to achieve. Accordingly, prior to complete inflation ofinner balloon 120, it is preferable to begin the process of injectingfluid 261 throughannular lumen 103. A fluid 261 is injected atport 201 and thereafter alongcatheter shaft 202 within lumen 321 (FIG. 3 ). Introduction offluid 261 is preferably not designed to generate sufficient inflation pressure ofouter balloon 130. The fluid 261 flows between the inner andouter balloons outer surface 231 ofinner balloon 220. As the fluid 261 (FIG. 1 ) contactsouter surface 231, it entrains (i.e., picks up) theantiproliferative 190 and thereby functions as a liquid carrier for the antiproliferative 190.Fluid 261 may be any suitable fluid that is biocompatible with theparticular antiproliferative 190 being used. In a preferred embodiment, the antiproliferative 190 being utilized is paclitaxel. The fluid 261 used for entraining the paclitaxel may include alcohol, ethanol, iodine contrast imaging agent, and saline. Othersuitable fluids 261 for entraining paclitaxel include medical grade saline solution and various Cremophore solvents. Thereafter, the fluid 261 with entrainedpaclitaxel 190 flows out throughpores 210 of theouter balloon 130 and into thestenosed region 180. Thepaclitaxel 190 may be applied to theouter surface 231 of theinner balloon 120 by coating. Thepaclitaxel 190 may be coated along the entireouter surface 231 ofinner balloon 120 in a variety of effective dosage amounts, including about 3 pg per mm2 of surface area of theouter surface 231. Between about 5 to about 10 cc offluid 261 may be introduced throughannular lumen 103 to entrain thepaclitaxel 190 throughpores 210 of theouter balloon 130. - As
inner balloon 120 is expanding, it pushes out against theouter balloon 130 to cause theouter balloon 130 to expand towards thestenosed vessel wall 180. At a certain juncture in the cryoplasty procedure,coolant 170 andfluid 261 may be simultaneously introduced through theirrespective lumens 322 and 321 (FIG. 3 ) ofcatheter shaft 202. Preferably, after the fluid 261 with entrainedpaclitaxel 190 outflows intovessel 180 throughpores 210, the outer surface of outer balloon 130 (FIG. 2 ) comes into direct contact withstenosed region 180 to cool the target tissue. Preferably, all of thepaclitaxel 190 is eluted into the target tissue of thestenosed vessel 180 prior to theouter balloon 130 contacting the tissue surrounding thestenosed region 180. Alternatively, elution may occur after or simultaneously with cooling oftissue surrounding region 180. - After completion of the elution of
paclitaxel 190 and the cooling of tissue bydual balloon assembly 100,fluid flow 261 andcoolant flow 170 may cease. At this juncture, thecoolant 170 gas within theinner balloon 120 is exhausted preferably by vacuum through exhaust lumen 325 (FIG. 3 ) ofcatheter shaft 202. - As described above, the combination of cryoplasty treatment with an antiproliferative 190 may reduce and/or eliminate vessel fractures, thereby inhibiting proliferative response after angioplasty procedures. The above procedure offers the advantage of the
dual balloon assembly 100 being pre-coated with the antiproliferative 190. As a result, the practitioner need not be concerned about injecting the antiproliferative 190 at a predetermined drug delivery rate during the procedure. - Excessive cooling of the
stenosed vessel wall 180 should be avoided because temperatures that are too cold may result in necrosis, a type of injury that yields cellular inflammation, cellular proliferation, and restenosis. Accordingly, theouter balloon 130 may be formed from a material that acts as a thermal insulator.FIGS. 1 and 2 show that athermal barrier 310 may be disposed along at least a portion of theouter surface 231 of theinner balloon 120. Suitablethermal barriers 310 may include textiles (e.g., polyethylene) as are commonly used in the art to form vascular grafts. Otherthermal barriers 310 may include polyethylene terepthalate (PET) or polyethylene napthlate (PEN) affixed to theouter surface 231 by adhesion bonding, heat welding, fasteners, or the like.FIG. 3 shows that thethermal barrier layer 310 is disposed between anouter surface 231 ofinner balloon 120 and theantiproliferative layer 190. Still further, thethermal barrier 310 may comprise a sleeve that is wrapped around theouter surface 231 ofinner balloon 120. - While preferred embodiments of the invention have been described, it should be understood that the invention is not so limited, and modifications may be made without departing from the invention. The scope of the invention is defined by the appended claims, and all devices that come within the meaning of the claims, either literally or by equivalence, are intended to be embraced therein. Furthermore, the advantages described above are not necessarily the only advantages of the invention, and it is not necessarily expected that all of the described advantages will be achieved with every embodiment of the invention.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/233,349 US8672919B2 (en) | 2008-09-18 | 2008-09-18 | Dual balloon catheter assembly |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/233,349 US8672919B2 (en) | 2008-09-18 | 2008-09-18 | Dual balloon catheter assembly |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100069900A1 true US20100069900A1 (en) | 2010-03-18 |
US8672919B2 US8672919B2 (en) | 2014-03-18 |
Family
ID=42007866
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/233,349 Active 2031-01-04 US8672919B2 (en) | 2008-09-18 | 2008-09-18 | Dual balloon catheter assembly |
Country Status (1)
Country | Link |
---|---|
US (1) | US8672919B2 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090254064A1 (en) * | 2008-04-08 | 2009-10-08 | Cook Incorporated | Weeping balloon catheter |
WO2010120620A1 (en) * | 2009-04-13 | 2010-10-21 | Cook Incorporated | Coated balloon catheter |
US20110060276A1 (en) * | 2007-09-12 | 2011-03-10 | Cook Incoporated | Balloon catheter for delivering a therapeutic agent |
US20110137245A1 (en) * | 2007-09-12 | 2011-06-09 | Cook Medical Technologies Llc | Balloon catheter with embedded rod |
US20110184399A1 (en) * | 2010-01-27 | 2011-07-28 | Medtronic Cryocath Lp | Partially compliant balloon device |
WO2012058158A1 (en) * | 2010-10-26 | 2012-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
EP2495007A1 (en) * | 2011-03-01 | 2012-09-05 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US20120279500A1 (en) * | 2009-11-13 | 2012-11-08 | Willy Rusch Gmbh | Tracheal Tube with Temperature Sensor |
US20130289549A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9078636B2 (en) | 2012-01-27 | 2015-07-14 | Medtronic Cryocath Lp | Cryo sensitizing agents for the enhancement of cryotherapy |
US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
US20150352337A1 (en) * | 2013-02-21 | 2015-12-10 | Olympus Corporation | Device for sustained release of liquid, endoscope having the same, and instrument for endoscopic surgery having the same |
US9510888B2 (en) * | 2011-10-27 | 2016-12-06 | Medtronic Cryocath Lp | Cryogenic balloon device with electroporation treatment region |
WO2018033920A1 (en) * | 2016-08-18 | 2018-02-22 | Angioslide Ltd. | Drug delivery catheter and method of use thereof |
US9956384B2 (en) | 2014-01-24 | 2018-05-01 | Cook Medical Technologies Llc | Articulating balloon catheter and method for using the same |
US10004550B2 (en) | 2010-08-05 | 2018-06-26 | Medtronic Ardian Luxembourg S.A.R.L. | Cryoablation apparatuses, systems, and methods for renal neuromodulation |
WO2018191013A1 (en) * | 2017-04-11 | 2018-10-18 | Cryterion Medical, Inc. | Pressure control assembly for cryogenic balloon catheter system |
US10124153B2 (en) | 2012-12-04 | 2018-11-13 | Angioslide Ltd. | Balloon catheter and methods of use thereof |
US10286190B2 (en) | 2013-12-11 | 2019-05-14 | Cook Medical Technologies Llc | Balloon catheter with dynamic vessel engaging member |
US10328290B2 (en) | 2012-08-03 | 2019-06-25 | Muffin Incorporated | Weeping balloon catheter with ultrasound element |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
US10588682B2 (en) | 2011-04-25 | 2020-03-17 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
CN111000616A (en) * | 2018-10-04 | 2020-04-14 | 尼尔拉维有限公司 | Reverse blood flow blocking flushing device |
WO2020155978A1 (en) * | 2019-01-31 | 2020-08-06 | 上海微创电生理医疗科技股份有限公司 | Balloon catheter and electrophysiological system |
US10898693B2 (en) | 2011-03-01 | 2021-01-26 | Sanovas Intellectual Property, Llc | Nasal delivery of agents with nested balloon catheter |
US10905490B2 (en) | 2012-04-27 | 2021-02-02 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
CN112869826A (en) * | 2021-01-06 | 2021-06-01 | 苏州中荟医疗科技有限公司 | Blood vessel recanalization system and method for angiostenosis lesion |
WO2021157806A1 (en) * | 2020-02-03 | 2021-08-12 | 주식회사 인성메디칼 | Catheter having temperature sensor |
EP3988042A4 (en) * | 2020-06-09 | 2022-08-10 | Accu Target Medipharma (Shanghai) Co., Ltd. | Double-layer freezing expansion balloon |
US11617543B2 (en) | 2019-12-30 | 2023-04-04 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
US11672457B2 (en) | 2018-11-24 | 2023-06-13 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
WO2023124594A1 (en) * | 2021-12-31 | 2023-07-06 | 苏州天鸿盛捷医疗器械有限公司 | Vascular stenosis treatment apparatus |
US11730385B2 (en) | 2019-08-08 | 2023-08-22 | Sentinel Medical Technologies, LLC | Cable for use with pressure monitoring catheters |
US11779263B2 (en) | 2019-02-08 | 2023-10-10 | Sentinel Medical Technologies, Llc. | Catheter for monitoring intra-abdominal pressure for assessing preeclampsia |
US11832947B2 (en) * | 2017-06-03 | 2023-12-05 | Sentinel Medical Technologies, LLC | Catheter for monitoring intra-abdominal pressure |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10350395B2 (en) | 2017-06-23 | 2019-07-16 | Cook Medical Technologies Llc | Introducer for lumen support or dilation |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US6428534B1 (en) * | 1999-02-24 | 2002-08-06 | Cryovascular Systems, Inc. | Cryogenic angioplasty catheter |
US6939320B2 (en) * | 1998-05-18 | 2005-09-06 | Boston Scientific Scimed., Inc. | Localized delivery of drug agents |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242397A (en) | 1989-06-20 | 1993-09-07 | Cedars-Sinai Medical Center | Catheter device and method of use for intramural delivery of protein kinase C and tyrosine protein kinase inhibitors to prevent restenosis after balloon angioplasty |
US5514092A (en) | 1994-08-08 | 1996-05-07 | Schneider (Usa) Inc. | Drug delivery and dilatation-drug delivery catheters in a rapid exchange configuration |
US6432102B2 (en) | 1999-03-15 | 2002-08-13 | Cryovascular Systems, Inc. | Cryosurgical fluid supply |
US6468297B1 (en) | 1999-02-24 | 2002-10-22 | Cryovascular Systems, Inc. | Cryogenically enhanced intravascular interventions |
US6955174B2 (en) | 2000-08-18 | 2005-10-18 | Uryovascular Systems, Inc. | Cryotherapy method for detecting and treating vulnerable plaque |
AU2002337596A1 (en) | 2001-09-27 | 2003-04-07 | Galil Medical Ltd. | Cryoplasty apparatus and method |
US7537580B2 (en) | 2004-06-23 | 2009-05-26 | Boston Scientific Scimed, Inc. | Intravascular dilatation infusion catheter |
US20060224115A1 (en) | 2005-03-30 | 2006-10-05 | Boston Scientific Scimed, Inc. | Balloon catheter with expandable wire lumen |
-
2008
- 2008-09-18 US US12/233,349 patent/US8672919B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4994033A (en) * | 1989-05-25 | 1991-02-19 | Schneider (Usa) Inc. | Intravascular drug delivery dilatation catheter |
US6939320B2 (en) * | 1998-05-18 | 2005-09-06 | Boston Scientific Scimed., Inc. | Localized delivery of drug agents |
US6428534B1 (en) * | 1999-02-24 | 2002-08-06 | Cryovascular Systems, Inc. | Cryogenic angioplasty catheter |
Cited By (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8784602B2 (en) | 2007-09-12 | 2014-07-22 | Cook Medical Technologies Llc | Balloon catheter for delivering a therapeutic agent |
US8182446B2 (en) | 2007-09-12 | 2012-05-22 | Cook Medical Technologies | Balloon catheter for delivering a therapeutic agent |
US20110060276A1 (en) * | 2007-09-12 | 2011-03-10 | Cook Incoporated | Balloon catheter for delivering a therapeutic agent |
US20110137245A1 (en) * | 2007-09-12 | 2011-06-09 | Cook Medical Technologies Llc | Balloon catheter with embedded rod |
US9174030B2 (en) | 2008-04-08 | 2015-11-03 | Cook Medical Technologies Llc | Weeping balloon catheter |
US8034022B2 (en) | 2008-04-08 | 2011-10-11 | Cook Medical Technologies Llc | Weeping balloon catheter |
US20090254064A1 (en) * | 2008-04-08 | 2009-10-08 | Cook Incorporated | Weeping balloon catheter |
US8911399B2 (en) | 2008-04-08 | 2014-12-16 | Cook Medical Technologies Llc | Weeping balloon catheter |
US8591461B2 (en) | 2008-04-08 | 2013-11-26 | Cook Medical Technologies Llc | Weeping balloon catheter |
WO2010120620A1 (en) * | 2009-04-13 | 2010-10-21 | Cook Incorporated | Coated balloon catheter |
US8740843B2 (en) | 2009-04-13 | 2014-06-03 | Cook Medical Technologies Llc | Coated balloon catheter |
US20120279500A1 (en) * | 2009-11-13 | 2012-11-08 | Willy Rusch Gmbh | Tracheal Tube with Temperature Sensor |
US20110184399A1 (en) * | 2010-01-27 | 2011-07-28 | Medtronic Cryocath Lp | Partially compliant balloon device |
US9089314B2 (en) * | 2010-01-27 | 2015-07-28 | Medtronic Cryocath Lp | Partially compliant balloon device |
US10004550B2 (en) | 2010-08-05 | 2018-06-26 | Medtronic Ardian Luxembourg S.A.R.L. | Cryoablation apparatuses, systems, and methods for renal neuromodulation |
US10188445B2 (en) | 2010-10-26 | 2019-01-29 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
CN102935009A (en) * | 2010-10-26 | 2013-02-20 | 美敦力阿迪安卢森堡有限责任公司 | Neuromodulation cryotherapeutic devices and associated systems and methods |
US10842547B2 (en) | 2010-10-26 | 2020-11-24 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US8945107B2 (en) | 2010-10-26 | 2015-02-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9439708B2 (en) | 2010-10-26 | 2016-09-13 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9060754B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9060755B2 (en) | 2010-10-26 | 2015-06-23 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US9066713B2 (en) | 2010-10-26 | 2015-06-30 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
WO2012058158A1 (en) * | 2010-10-26 | 2012-05-03 | Medtronic Ardian Luxembourg S.A.R.L. | Neuromodulation cryotherapeutic devices and associated systems and methods |
US10898693B2 (en) | 2011-03-01 | 2021-01-26 | Sanovas Intellectual Property, Llc | Nasal delivery of agents with nested balloon catheter |
US9186485B2 (en) | 2011-03-01 | 2015-11-17 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US8348890B2 (en) | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
EP2495007A1 (en) * | 2011-03-01 | 2012-09-05 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US10588682B2 (en) | 2011-04-25 | 2020-03-17 | Medtronic Ardian Luxembourg S.A.R.L. | Apparatus and methods related to constrained deployment of cryogenic balloons for limited cryogenic ablation of vessel walls |
US10945780B2 (en) | 2011-10-27 | 2021-03-16 | Medtronic Cryocath Lp | Cryogenic balloon device with electroporation treatment region |
US11690662B2 (en) | 2011-10-27 | 2023-07-04 | Medtronic Cryocath Lp | Cryogenic balloon device with radiofrequency treatment region |
US9510888B2 (en) * | 2011-10-27 | 2016-12-06 | Medtronic Cryocath Lp | Cryogenic balloon device with electroporation treatment region |
US9808304B2 (en) | 2011-10-27 | 2017-11-07 | Medtronic Cryocath Lp | Cryogenic balloon device with electroporation treatment region |
US9078636B2 (en) | 2012-01-27 | 2015-07-14 | Medtronic Cryocath Lp | Cryo sensitizing agents for the enhancement of cryotherapy |
US9241752B2 (en) * | 2012-04-27 | 2016-01-26 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US9872718B2 (en) * | 2012-04-27 | 2018-01-23 | Medtronic Adrian Luxembourg S.a.r.l. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US10905490B2 (en) | 2012-04-27 | 2021-02-02 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
CN104244854A (en) * | 2012-04-27 | 2014-12-24 | 美敦力阿迪安卢森堡有限公司 | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US11751931B2 (en) | 2012-04-27 | 2023-09-12 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices for renal neuromodulation and associated systems and methods |
US20160166305A1 (en) * | 2012-04-27 | 2016-06-16 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts With Pressure Relief in Cryotherapeutic Catheters and Associated Devices, Systems, and Methods |
US20130289549A1 (en) * | 2012-04-27 | 2013-10-31 | Medtronic Ardian Luxembourg S.A.R.L. | Shafts with pressure relief in cryotherapeutic catheters and associated devices, systems, and methods |
US10328290B2 (en) | 2012-08-03 | 2019-06-25 | Muffin Incorporated | Weeping balloon catheter with ultrasound element |
US9095321B2 (en) | 2012-11-21 | 2015-08-04 | Medtronic Ardian Luxembourg S.A.R.L. | Cryotherapeutic devices having integral multi-helical balloons and methods of making the same |
US10124153B2 (en) | 2012-12-04 | 2018-11-13 | Angioslide Ltd. | Balloon catheter and methods of use thereof |
US9017317B2 (en) | 2012-12-06 | 2015-04-28 | Medtronic Ardian Luxembourg S.A.R.L. | Refrigerant supply system for cryotherapy including refrigerant recompression and associated devices, systems, and methods |
US20150352337A1 (en) * | 2013-02-21 | 2015-12-10 | Olympus Corporation | Device for sustained release of liquid, endoscope having the same, and instrument for endoscopic surgery having the same |
US10286190B2 (en) | 2013-12-11 | 2019-05-14 | Cook Medical Technologies Llc | Balloon catheter with dynamic vessel engaging member |
US9956384B2 (en) | 2014-01-24 | 2018-05-01 | Cook Medical Technologies Llc | Articulating balloon catheter and method for using the same |
US10492842B2 (en) | 2014-03-07 | 2019-12-03 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
US11406437B2 (en) | 2014-03-07 | 2022-08-09 | Medtronic Ardian Luxembourg S.A.R.L. | Monitoring and controlling internally administered cryotherapy |
WO2018033920A1 (en) * | 2016-08-18 | 2018-02-22 | Angioslide Ltd. | Drug delivery catheter and method of use thereof |
WO2018191013A1 (en) * | 2017-04-11 | 2018-10-18 | Cryterion Medical, Inc. | Pressure control assembly for cryogenic balloon catheter system |
US11832947B2 (en) * | 2017-06-03 | 2023-12-05 | Sentinel Medical Technologies, LLC | Catheter for monitoring intra-abdominal pressure |
CN111000616A (en) * | 2018-10-04 | 2020-04-14 | 尼尔拉维有限公司 | Reverse blood flow blocking flushing device |
US11253287B2 (en) * | 2018-10-04 | 2022-02-22 | Neuravi Limited | Retrograde blood flow occlusion flushing device |
US11672457B2 (en) | 2018-11-24 | 2023-06-13 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
WO2020155978A1 (en) * | 2019-01-31 | 2020-08-06 | 上海微创电生理医疗科技股份有限公司 | Balloon catheter and electrophysiological system |
US11779263B2 (en) | 2019-02-08 | 2023-10-10 | Sentinel Medical Technologies, Llc. | Catheter for monitoring intra-abdominal pressure for assessing preeclampsia |
US11730385B2 (en) | 2019-08-08 | 2023-08-22 | Sentinel Medical Technologies, LLC | Cable for use with pressure monitoring catheters |
US11617543B2 (en) | 2019-12-30 | 2023-04-04 | Sentinel Medical Technologies, Llc. | Catheter for monitoring pressure |
WO2021157806A1 (en) * | 2020-02-03 | 2021-08-12 | 주식회사 인성메디칼 | Catheter having temperature sensor |
US11679239B2 (en) * | 2020-06-09 | 2023-06-20 | Accutarget Medipharma (Shanghai) Co., Ltd. | Double-layer cryogenic inflatable balloon |
JP7282251B2 (en) | 2020-06-09 | 2023-05-26 | 上海導向医療系統有限公司 | double layer cryoexpansion balloon |
US20220273917A1 (en) * | 2020-06-09 | 2022-09-01 | Accutarget Medipharma (Shanghai) Co., Ltd. | Double-layer cryogenic inflatable balloon |
EP3988042A4 (en) * | 2020-06-09 | 2022-08-10 | Accu Target Medipharma (Shanghai) Co., Ltd. | Double-layer freezing expansion balloon |
CN112869826A (en) * | 2021-01-06 | 2021-06-01 | 苏州中荟医疗科技有限公司 | Blood vessel recanalization system and method for angiostenosis lesion |
WO2023124594A1 (en) * | 2021-12-31 | 2023-07-06 | 苏州天鸿盛捷医疗器械有限公司 | Vascular stenosis treatment apparatus |
Also Published As
Publication number | Publication date |
---|---|
US8672919B2 (en) | 2014-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8672919B2 (en) | Dual balloon catheter assembly | |
US7022120B2 (en) | Cryoplasty device and method | |
US8715274B2 (en) | Regulating internal pressure of a cryotherapy balloon catheter | |
US5971979A (en) | Method for cryogenic inhibition of hyperplasia | |
JP4887141B2 (en) | Balloon therapy system with controllable pressure and temperature | |
US6458098B1 (en) | Vascular therapy device | |
US8177779B2 (en) | Controllable pressure cryogenic balloon treatment system and method | |
DE60131174T2 (en) | CRYOTHERAPY CATHETER WITH IMPROVED SAFETY | |
US6733474B2 (en) | Catheter for tissue dilatation and drug delivery | |
US5035705A (en) | Method of purging a balloon catheter | |
US20090171284A1 (en) | Dilation system | |
EP3600181A1 (en) | Cryogenic balloon pressure sensor assembly | |
JP2002538882A (en) | Cryosurgical fluid supply | |
EP2353632B1 (en) | Medical device for local drug delivery | |
JP2014514079A (en) | Plaque stabilization using cryoenergy | |
CA2244038A1 (en) | Prepared catheter | |
US20130144263A1 (en) | Balloon catheter system | |
MXPA97006545A (en) | Device for loading and centering a vascular radiation therapy source |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COOK INCORPORATED,INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIRLEY, GARY BRADFORD;MOORE, WILLIAM F.;REEL/FRAME:021601/0108 Effective date: 20080916 Owner name: COOK INCORPORATED, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SHIRLEY, GARY BRADFORD;MOORE, WILLIAM F.;REEL/FRAME:021601/0108 Effective date: 20080916 |
|
AS | Assignment |
Owner name: COOK MEDICAL TECHNOLOGIES LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COOK INCORPORATED;REEL/FRAME:032059/0355 Effective date: 20140127 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNOR:COOK MEDICAL TECHNOLOGIES LLC;REEL/FRAME:066700/0277 Effective date: 20240227 |